Ironwood Pharmaceuticals Total Assets 2010-2023 | IRWD

Ironwood Pharmaceuticals total assets from 2010 to 2023. Total assets can be defined as the sum of all assets on a company's balance sheet.
Ironwood Pharmaceuticals Annual Total Assets
(Millions of US $)
2023 $471
2022 $1,101
2021 $1,127
2020 $559
2019 $403
2018 $332
2017 $606
2016 $710
2015 $619
2014 $329
2013 $279
2012 $230
2011 $209
2010 $301
2009 $162
Ironwood Pharmaceuticals Quarterly Total Assets
(Millions of US $)
2023-12-31 $471
2023-09-30 $524
2023-06-30 $603
2023-03-31 $1,155
2022-12-31 $1,101
2022-09-30 $1,040
2022-06-30 $976
2022-03-31 $1,083
2021-12-31 $1,127
2021-09-30 $1,079
2021-06-30 $1,007
2021-03-31 $599
2020-12-31 $559
2020-09-30 $492
2020-06-30 $444
2020-03-31 $404
2019-12-31 $403
2019-09-30 $334
2019-06-30 $316
2019-03-31 $364
2018-12-31 $332
2018-09-30 $417
2018-06-30 $618
2018-03-31 $571
2017-12-31 $606
2017-09-30 $625
2017-06-30 $705
2017-03-31 $701
2016-12-31 $710
2016-09-30 $732
2016-06-30 $700
2016-03-31 $603
2015-12-31 $619
2015-09-30 $613
2015-06-30 $654
2015-03-31 $306
2014-12-31 $329
2014-09-30 $346
2014-06-30 $371
2014-03-31 $419
2013-12-31 $279
2013-09-30 $326
2013-06-30 $384
2013-03-31 $325
2012-12-31 $230
2012-09-30 $247
2012-06-30 $209
2012-03-31 $249
2011-12-31 $209
2011-09-30 $219
2011-06-30 $250
2011-03-31 $272
2010-12-31 $301
2010-09-30 $305
2010-06-30 $322
2010-03-31 $338
2009-12-31 $162
2009-09-30 $150
2009-06-30 $0
2009-03-31 $0
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $1.271B $0.443B
Ironwood Pharmaceuticals, Inc. focuses on the development and commercialization of treatments primarily addressing gastrointestinal diseases. Linzess was launched in collaboration with Allergan for patients suffering from irritable bowel syndrome (IBS-C; 290 mcg) with constipation or chronic idiopathic constipation. Ironwood and AbbVie co-develop & co-commercialize Linzess in all other territories world wide. Linzess is marketed by Allergan for IBS-C in Europe and Canada under the brand name Constella. The company receives royalties on sales of Constella in Europe and Canada from AbbVie. In Japan, it has partnered with Astellas Pharma for the development and commercialization of Linzess and with AstraZeneca in China, Hong Kong & Macau. Linzess received approval for IBS-C indication in Japan for chronic constipation and in China for IBS-C. The company completed the spin-off of its soluble guanylate cyclase segment into a separate, publicly traded company, Cyclerion Therapeutics.
Stock Name Country Market Cap PE Ratio
Zoetis (ZTS) United States $76.411B 31.00
Chugai Pharmaceutical (CHGCY) Japan $54.679B 24.44
Takeda Pharmaceutical (TAK) Japan $42.314B 6.86
Merck (MKGAF) Germany $20.967B 19.78
Astellas Pharma (ALPMY) Japan $18.169B 28.69
Sandoz Group AG (SDZNY) Switzerland $14.745B 0.00
Neurocrine Biosciences (NBIX) United States $14.161B 38.76
Shionogi (SGIOY) Japan $14.115B 12.66
United Therapeutics (UTHR) United States $11.642B 12.41
Catalent (CTLT) United States $10.225B 0.00
Cerevel Therapeutics Holdings (CERE) United States $7.726B 0.00
Jazz Pharmaceuticals (JAZZ) Ireland $6.935B 7.62
Revolution Medicines (RVMD) United States $6.854B 0.00
Ionis Pharmaceuticals (IONS) United States $6.117B 0.00
Hikma Pharmaceuticals Plc (HKMPF) United Kingdom $5.396B 0.00
Orion OYJ (ORINY) Finland $4.940B 20.83
Madrigal Pharmaceuticals (MDGL) United States $4.892B 0.00
Alpine Immune Sciences (ALPN) United States $4.235B 0.00
Crinetics Pharmaceuticals (CRNX) United States $3.717B 0.00
Summit Therapeutics (SMMT) United States $3.082B 0.00
Arrowhead Pharmaceuticals (ARWR) United States $3.028B 0.00
Corcept Therapeutics (CORT) United States $2.553B 23.13
PTC Therapeutics (PTCT) United States $2.532B 0.00
Indivior (INDV) United States $2.475B 11.73
Dyne Therapeutics (DYN) United States $2.248B 0.00
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $2.075B 11.86
Recursion Pharmaceuticals (RXRX) United States $2.074B 0.00
Ardelyx (ARDX) United States $2.040B 0.00
NewAmsterdam Pharma (NAMS) Netherlands $1.948B 0.00
Evotec AG (EVO) Germany $1.868B 0.00
Fusion Pharmaceuticals (FUSN) Canada $1.820B 0.00
Catalyst Pharmaceuticals (CPRX) United States $1.737B 17.95
Avadel Pharmaceuticals (AVDL) Ireland $1.705B 0.00
Taro Pharmaceutical Industries (TARO) Israel $1.596B 27.93
Soleno Therapeutics (SLNO) United States $1.508B 0.00
Xencor (XNCR) United States $1.486B 0.00
4D Molecular Therapeutics (FDMT) United States $1.350B 0.00
Pacira BioSciences (PCRX) United States $1.266B 12.60
Collegium Pharmaceutical (COLL) United States $1.227B 7.55
Enliven Therapeutics (ELVN) United States $1.065B 0.00
Cronos Group (CRON) Canada $1.024B 0.00
Ocular Therapeutix (OCUL) United States $0.955B 0.00
Cassava Sciences (SAVA) United States $0.954B 0.00
Centessa Pharmaceuticals (CNTA) United Kingdom $0.950B 0.00
ARS Pharmaceuticals (SPRY) United States $0.945B 0.00
Relay Therapeutics (RLAY) United States $0.932B 0.00
BioCryst Pharmaceuticals (BCRX) United States $0.918B 0.00
USANA Health Sciences (USNA) United States $0.876B 14.19
Sage Therapeutics (SAGE) United States $0.839B 0.00
Aurinia Pharmaceuticals Inc (AUPH) Canada $0.729B 0.00
Siga Technologies (SIGA) United States $0.722B 10.68
Silence Therapeutics (SLN) United Kingdom $0.658B 0.00
Savara (SVRA) United States $0.650B 0.00
Lyell Immunopharma (LYEL) United States $0.602B 0.00
Calliditas Therapeutics AB (CALT) Sweden $0.596B 0.00
Exscientia (EXAI) United Kingdom $0.565B 0.00
OmniAb (OABI) United States $0.547B 0.00
Verve Therapeutics (VERV) United States $0.538B 0.00
Altimmune (ALT) United States $0.518B 0.00
KalVista Pharmaceuticals (KALV) United States $0.512B 0.00
ProKidney (PROK) United States $0.505B 0.00
Larimar Therapeutics (LRMR) United States $0.495B 0.00
Korro Bio (KRRO) United States $0.467B 0.00
Theravance Biopharma (TBPH) Cayman Islands $0.459B 0.00
Lexeo Therapeutics (LXEO) United States $0.421B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.407B 0.00
Tourmaline Bio (TRML) United States $0.406B 0.00
Esperion Therapeutics (ESPR) United States $0.394B 0.00
Heron Therapeutics (HRTX) United States $0.393B 0.00
Harrow (HROW) United States $0.367B 0.00
Black Diamond Therapeutics (BDTX) United States $0.366B 0.00
Nature's Sunshine Products (NATR) United States $0.359B 20.06
Organogenesis (ORGO) United States $0.329B 62.25
Enanta Pharmaceuticals (ENTA) United States $0.321B 0.00
Aquestive Therapeutics (AQST) United States $0.320B 0.00
Bioventus (BVS) United States $0.314B 0.00
Fractyl Health (GUTS) United States $0.312B 0.00
Verrica Pharmaceuticals (VRCA) United States $0.308B 0.00
ESSA Pharma (EPIX) Canada $0.304B 0.00
Nektar Therapeutics (NKTR) United States $0.288B 0.00
Nanobiotix S.A (NBTX) France $0.288B 0.00
Akebia Therapeutics (AKBA) United States $0.287B 0.00
Eliem Therapeutics (ELYM) United States $0.282B 0.00
Xeris Biopharma Holdings (XERS) United States $0.280B 0.00
Pyxis Oncology (PYXS) United States $0.258B 0.00
Foghorn Therapeutics (FHTX) United States $0.255B 0.00
Adherex Technologies (FENC) United States $0.252B 0.00
Aldeyra Therapeutics (ALDX) United States $0.247B 0.00
Lyra Therapeutics (LYRA) United States $0.246B 0.00
Metagenomi (MGX) United States $0.237B 0.00
Avita Medical (RCEL) United States $0.226B 0.00
Conduit Pharmaceuticals (CDT) United States $0.221B 0.00
Acrivon Therapeutics (ACRV) United States $0.217B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.210B 0.00
Zevra Therapeutics (ZVRA) United States $0.209B 0.00
Galectin Therapeutics (GALT) United States $0.207B 0.00
Century Therapeutics (IPSC) United States $0.196B 0.00
Telomir Pharmaceuticals (TELO) United States $0.184B 0.00
Profound Medical (PROF) Canada $0.180B 0.00
MediWound (MDWD) Israel $0.177B 0.00
Regulus Therapeutics (RGLS) United States $0.173B 0.00
Innate Pharma SA (IPHYF) France $0.171B 0.00
Prelude Therapeutics (PRLD) United States $0.162B 0.00
Achieve Life Sciences (ACHV) Canada $0.162B 0.00
Incannex Healthcare (IXHL) Australia $0.152B 0.00
CytoDyn (CYDY) United States $0.146B 0.00
Elite Pharmaceuticals (ELTP) United States $0.139B 12.98
Amylyx Pharmaceuticals (AMLX) United States $0.138B 2.90
Cardiol Therapeutics (CRDL) Canada $0.136B 0.00
Karyopharm Therapeutics (KPTI) United States $0.132B 0.00
VAXART, INC (VXRT) United States $0.129B 0.00
GlycoMimetics (GLYC) United States $0.118B 0.00
OptiNose (OPTN) United States $0.114B 0.00
FibroGen (FGEN) United States $0.113B 0.00
Citius Pharmaceuticals (CTXR) United States $0.112B 0.00
Relmada Therapeutics (RLMD) United States $0.111B 0.00
Inotiv (NOTV) United States $0.110B 0.00
PMV Pharmaceuticals (PMVP) United States $0.102B 0.00
Assertio Holdings (ASRT) United States $0.098B 7.92
Vivani Medical (VANI) United States $0.098B 0.00
ProPhase Labs (PRPH) United States $0.098B 0.00
Aclaris Therapeutics (ACRS) United States $0.097B 0.00
AlloVir (ALVR) United States $0.092B 0.00
Reviva Pharmaceuticals Holdings (RVPH) United States $0.089B 0.00
Jaguar Animal Health (JAGX) United States $0.088B 0.00
ARYA Sciences Acquisition Corp IV (ARYD) United States $0.086B 0.00
Marinus Pharmaceuticals (MRNS) United States $0.083B 0.00
Tempest Therapeutics (TPST) United States $0.082B 0.00
Journey Medical (DERM) United States $0.074B 0.00
Champions Oncology (CSBR) United States $0.070B 0.00
Carisma Therapeutics (CARM) United States $0.067B 0.00
SCYNEXIS (SCYX) United States $0.067B 0.99
Mural Oncology (MURA) Ireland $0.065B 0.00
Reneo Pharmaceuticals (RPHM) United States $0.058B 0.00
BioLineRx (BLRX) Israel $0.054B 0.00
Gain Therapeutics (GANX) United States $0.053B 0.00
Unicycive Therapeutics (UNCY) United States $0.042B 0.00
Rafael Holdings (RFL) United States $0.040B 0.00
Natural Alternatives (NAII) United States $0.038B 0.00
ElectroCore (ECOR) United States $0.038B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.038B 0.00
CASI Pharmaceuticals (CASI) China $0.037B 0.00
VYNE Therapeutics (VYNE) United States $0.037B 0.00
DURECT (DRRX) United States $0.036B 0.00
JanOne (JAN) United States $0.034B 0.00
Protara Therapeutics (TARA) United States $0.033B 0.00
Surrozen (SRZN) United States $0.032B 0.00
Viracta Therapeutics (VIRX) United States $0.032B 0.00
Enlivex Therapeutics (ENLV) Israel $0.030B 0.00
Nutriband (NTRB) United States $0.027B 0.00
Oncternal Therapeutics (ONCT) United States $0.026B 0.00
Iterum Therapeutics (ITRM) Ireland $0.026B 0.00
Lipocine (LPCN) United States $0.025B 0.00
PolyPid (PYPD) Israel $0.024B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.022B 10.53
NRx Pharmaceuticals (NRXP) United States $0.022B 0.00
TherapeuticsMD (TXMD) United States $0.022B 0.00
Alaunos Therapeutics (TCRT) United States $0.021B 0.00
MEI Pharma (MEIP) United States $0.020B 1.03
CERo Therapeutics Holdings (CERO) United States $0.020B 0.00
Aptorum Group (APM) United Kingdom $0.020B 0.00
BioVie (BIVI) United States $0.020B 0.00
Nuvilex (PMCB) United States $0.018B 0.00
Talphera (TLPH) United States $0.017B 0.00
Indaptus Therapeutics (INDP) United States $0.017B 0.00
Minerva Neurosciences (NERV) United States $0.017B 0.00
Traws Pharma (TRAW) United States $0.016B 0.00
Tonix Pharmaceuticals Holding (TNXP) United States $0.016B 0.00
Mannatech (MTEX) United States $0.015B 0.00
Avalo Therapeutics (AVTX) United States $0.015B 0.00
XTL Biopharmaceuticals (XTLB) Israel $0.014B 0.00
Dominari Holdings (DOMH) United States $0.014B 0.00
Kiora Pharmaceuticals (KPRX) United States $0.013B 0.00
Redhill Biopharma (RDHL) Israel $0.013B 0.00
Cosmos Health (COSM) Greece $0.012B 0.00
Molecular Templates (MTEM) United States $0.011B 0.00
Addex Therapeutics (ADXN) Switzerland $0.009B 0.00
Biomerica (BMRA) United States $0.009B 0.00
Inhibikase Therapeutics (IKT) United States $0.009B 0.00
Vivos Therapeutics (VVOS) United States $0.008B 0.00
Universe Pharmaceuticals INC (UPC) China $0.008B 0.00
Plus Therapeutics (PSTV) United States $0.008B 0.00
Shuttle Pharmaceuticals Holdings (SHPH) United States $0.007B 0.00
MyMD Pharmaceuticals (MYMD) United States $0.007B 0.00
Xenetic Biosciences (XBIO) United States $0.007B 0.00
Mangoceuticals (MGRX) United States $0.007B 0.00
Ainos (AIMD) United States $0.006B 0.00
Heatwurx (PCSA) United States $0.006B 0.00
XORTX Therapeutics (XRTX) Canada $0.005B 0.00
SHINECO (SISI) China $0.005B 0.00
TransCode Therapeutics (RNAZ) United States $0.005B 0.00
Petros Pharmaceuticals (PTPI) United States $0.005B 0.00
Acutus Medical (AFIB) United States $0.004B 0.00
Phio Pharmaceuticals (PHIO) United States $0.004B 0.00
Finch Therapeutics (FNCH) United States $0.004B 0.00
Clever Leaves Holdings (CLVR) Canada $0.003B 0.00
Quoin Pharmaceuticals (QNRX) United States $0.003B 0.00
Avenue Therapeutics (ATXI) United States $0.003B 0.00
Altamira Therapeutics (CYTO) Bermuda $0.003B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.002B 0.00
60 Degrees Pharmaceuticals (SXTP) United States $0.002B 0.00
Salarius Pharmaceuticals (SLRX) United States $0.002B 0.00
Clearmind Medicine (CMND) Canada $0.002B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.002B 0.00
Qualigen Therapeutics (QLGN) United States $0.002B 0.00
Bio-Path Holdings (BPTH) United States $0.002B 0.00
PainReform (PRFX) Israel $0.002B 0.00
InMed Pharmaceuticals (INM) Canada $0.001B 0.00
SciSparc (SPRC) Israel $0.001B 0.00
Aditxt (ADTX) United States $0.001B 0.00
China SXT Pharmaceuticals (SXTC) China $0.000B 0.00
Qilian Holding Group (QLI) China $0.000B 0.00
Context Therapeutics (CNTX) United States $0.000B 0.00
Grifols, S.A (GRFS) Spain $0.000B 0.00
4D Pharma (LBPS) United Kingdom $0.000B 0.00
NLS Pharmaceutics (NLSP) Switzerland $0.000B 0.00
Procaps Group, S.A (PROC) Luxembourg $0.000B 5.42
Patheon (PTHN) Netherlands $0.000B 0.00
RVL Pharmaceuticals (RVLP) United States $0.000B 0.00
Stevanato Group S.p.A (STVN) Italy $0.000B 42.66